Orthodenticle homolog 2 (OTX2) is a homeobox family transcription factor required for brain and eye formation. Various genetic alterations in OTX2 have been described, mostly in patients with severe ocular malformations. In order to expand the knowledge of the spectrum of OTX2 mutation, we performed OTX2 mutation screening in 92 patients with combined pituitary hormone deficiency (CPHD). We directly sequenced the coding regions and exon-intron boundaries of OTX2 in 92 CPHD patients from the Dutch HYPOPIT study in whom mutations in the classical CPHD genes PROP1, POU1F1, HESX1, LHX3, and LHX4 had been ruled out. Among 92 CPHD patients, we identified a novel heterozygous missense mutation c.401COG (p.Pro134Arg) in a patient with CPHD, pituitary malformation, and an underdeveloped left optic nerve. Binding of both the wild-type and mutant OTX2 proteins to bicoid binding sites was equivalent; however, the mutant OTX2 exhibited decreased transactivation. We describe a novel missense heterozygous OTX2 mutation that acts as a dominant negative inhibitor of target gene expression in a patient with CPHD, pituitary malformation, and optic nerve hypoplasia. We provide an overview of all OTX2 mutations described till date, which show that OTX2 is a promising candidate gene for genetic screening of patients with CPHD or isolated GH deficiency (IGHD). As the majority of the OTX2 mutations found in patients with CPHD, IGHD, or short stature have been found in exon 5, we recommend starting mutational screening in those patients in exon 5 of the gene.
Introduction
Orthodenticle Drosophila homolog 2 (OTX2; MIM 600037), is a homeobox family transcription factor, which is required for brain and eye formation. OTX2 is located in chromosome 14q and has five exons of which three are coding. There are two known isoforms: a (NM_021728.2; NP_068374.1) and b (NM_172337.1; NP_758840.1); isoform b is the major product of the gene and has eight fewer amino acids than isoform a. In the mouse, during early development, Otx2 is expressed in the forebrain and midbrain and has a role in the development of the brain, face, and skull (1, 2, 3) .
Various genetic alterations in OTX2 have been described, including interstitial deletions (4, 5) , microdeletions (6, 7) , frameshift, and point mutations (8) . The majority of the alterations are found in patients with severe ocular malformations such as anophthalmia (AO), microphthalmia (MO), Leber congenital amaurosis, or coloboma (6, 8, 9, 10) . OTX2 has been shown to be important for the regulation of HESX homeobox 1 (HESX1) (11, 12) , one of the transcription factors involved in pituitary development. As HESX1 mutations have been described in patients with isolated GH deficiency (IGHD) and combined pituitary hormone deficiency (CPHD), several recent studies also performed mutation and deletion screening of OTX2 in patients with variable degrees of pituitary dysfunction (7, 13, 14, 15, 16, 17) . In the majority of the patients, but not all (14) , eye malformations were also present.
CPHD is any combination of two or more anterior pituitary hormone deficiencies. Mutations in several genes encoding the transcription factors involved in pituitary cell differentiation have been associated with CPHD (for review, see (18) ). However, in the majority of CPHD patients, causative gene mutations remain unknown. Thus, in order to expand the mutation spectrum of CPHD, we performed mutation analysis of OTX2 in a cohort of 92 CPHD patients from the Dutch HYPOPIT study. We describe a new OTX2 mutation found in one of our patients with CPHD, who also had pituitary malformation and an underdeveloped left optic nerve. In addition to this new finding, we provide an overview of all phenotypic and genetic data reported to date.
Materials and methods
DNA samples were collected from 92 patients with CPHD, who participated in the Dutch HYPOPIT study (19) . These patients had been recruited from the Endocrinology Departments of six university and two non-university Hospitals and had been registered in the Dutch National Registry of Growth Hormone Treatment between 1992 and 2003. All patients had deficiencies of GH and of one or more additional hormonal axes. Deficiencies of hypothalamic-pituitarythyroidal, -adrenal, and -gonadal axes were defined by an abnormal TRH test or TSH levels that were low or inadequately low free-tetraiodothyronine (FT 4 ); abnormal CRF/ACTH/glucagon test or ACTH levels that were low or inadequately low cortisol and LH, FSH, estrogen/testosterone, or inappropriately low gonadotropin response to LHRH for age or lack of spontaneous puberty after the age of 14 years. Prolactin deficiency was defined as abnormal prolactin during random sampling or TRH testing. Reference values from the individual hospitals were used. Exclusion criteria included patients with a known cause of CPHD, such as a brain tumor, brain surgery, brain radiation, or known syndromes. Written informed consent was obtained from all participating patients and their parents or legal guardian.
DNA was isolated from the whole blood collected in EDTA tubes according to standard procedures. OTX2 (NM_021728.2) PCR amplification and sequencing was performed as described previously (20) .
Generation of plasmids
The OTX2 cDNA was cloned into the expression vector pSG5, and the multiple bicoid binding site was placed into the luciferase-containing pGL2 promoter vector (Promega Corp.) (14) . The OTX2 Pro134Arg mutation was designed according to the QuickChange Site-direct mutagenesis protocol (Stratagene) after introducing a single base change using specific primers (available on request). After DNA amplification and Maxiprep kit purification (Qiagen), the sequence, orientation, and presence of the mutation in the plasmid were confirmed by DNA sequencing.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed with OTX2 recombinant proteins and 32 Plabeled DNA fragments as described previously (14) . Wild-type (WT) and Pro134Arg mutation proteins were synthesized using the TNT-coupled transcription and translation reticulocyte lysate system with T7 polymerase, according to the manufacturer's protocol (Promega Corp.). To determine OTX2 DNA binding, a consensus OTX2 DNA binding site was used. These oligonucleotides were g 32 P-end labeled with T 4 polynucleotide kinase. For each EMSA, in vitro-translated proteins were mixed with radiolabeled probe for 30 min at room temperature, along with deoxyinosine-deoxycytosine, salmon sperm, and binding buffer (50 mM KCl, 20% glycerol, and 20 mM HEPES (pH 7.6-7.8)). Each sample was then separated by gel electrophoresis on a 5% nondenaturing acrylamide gel and analyzed by autoradiography. The OTX2 complexes were supershifted with a polyclonal OTX2 antibody. The binding was competed by addition of the unlabeled oligonucleotide in excess. 35S-Methionine was added to our reticulocyte lysate system to confirm the efficiency of protein synthesis. The radiolabeled proteins were resolved on a 10% denaturing acrylamide gel and analyzed by autoradiography.
Transient transfection and cell culture
Transient transfections were performed in 293T and GN cell lines. Cells were maintained in DMEM high glucose 1! (4.5 g/l D-glucose; Life Technologies, Inc.), supplemented with L-glutamine, 1% antibiotic-antimycotic (100!; Life Technologies), 110 mg/l sodium pyruvate, and 10% fetal bovine serum (Life Technologies). Cells were grown at 37 8C in 5% CO 2 and were transfected at 40-60% confluency. Total DNA was kept constant, and nonspecific effects of viral promoters were controlled using the empty pSG5 vector (pSG5EV). Luciferase activity in relative light units was measured at 48 h using the Lumat LB 9507 (Berthold Technologies, Oak Ridge, TN, USA).
293T transient transfections were performed in sixwell tissue culture plates using lipofectamine reagent (Invitrogen). For functional studies, the pSG5-mOTX2 cDNA or the pSG5-MUT mOTX2 cDNA was used. A total of 125 ng of a multiple bicoid binding site promoter luciferase vector (or the pGL2 empty vector (pGL2EV)) was cotransfected with 125 ng WT OTX2, 62.5 ng pSG5EV/62.5 ng WT OTX2, 31.25 ng pSG5EV/62.5 ng WT OTX2/31.25 ng MUT OTX2, 62.5 ng WT OTX2/62.5 ng MUT OTX2, or 125 ng MUT OTX2. This same experiment design was repeated using GN cells.
Transfections were performed in triplicate for each condition within a single experiment, and experiments were repeated at least three times using different plasmid preparations for each construct. The relative luciferase activity for each control (pGL2EV) was set to 1, and results were expressed as fold-promoter activation and represented as the S.E.M. of representative experiments.
Statistical analysis
Transient transfection results are expressed as the S.E.M. Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software, Inc., San Diego, CA, USA). The data were normalized to empty vector expression and graphs depict fold change over empty vector. Group means were compared using single ANOVA and Tukey's multiple comparison test, with P!0.05 considered statistically significant.
Results
We directly sequenced the complete coding region and intron-exon boundaries of OTX2 in DNA samples from 92 patients with CPHD, in whom mutations in the classical CPHD genes PROP1, POU1F1, HESX1, LHX3, and LHX4 had been ruled out (19) . Clinical characteristics and magnetic resonance imaging (MRI) data of the patients have been published previously (19) .
In one patient, we identified a new missense mutation c.401COG in exon 5, which replaces proline (CCC) with arginine (CGC) at amino acid position 134 ( Fig. 1A) .
The mutation is heterozygous and inherited from the phenotypically normal father. Additionally, we identified a synonymous variant c.792COT (p.Z) in another CPHD patient ( Fig. 1B ). Finally, our sequencing results showed two known polymorphisms: rs2277499 in exon 4 (minor allele frequency 36%) and rs171978 in exon 5 (minor allele frequency 7%).
Clinical features
The patient carrying the OTX2 p.Pro134Arg mutation is a male born from Dutch Caucasian non-consanguineous parents after 40 weeks of gestation. His birth length was 50 cm and his birth weight 3600 g. He had neonatal hypoglycemia. His MRI showed a normal anterior pituitary, but an ectopic posterior pituitary, an absence of pituitary stalk, and an underdeveloped left optic nerve. At the age of 8 years, clonidine test showed a GH peak of 3.4 mU/l (normal peak above 20 mU/l). Before the initiation of GH treatment, his insulin-like growth factor 1 (IGF1) was 1.9 nmol/l (K5.3 SDS) and IGFBP3 0.6 mg/l (K6.7 SDS). GH supplementation was started at the age of 8 years when his height was 1.15 m (K3.2 SDS). At the initiation of GH treatment, his bone age delay was 3.5 years. Central hypothyroidism was detected at the age of 9 years, based on a FT 4 level of 8.0 pmol/l (normal range 12-26 pmol/l) and an abnormally low TSH for this low FT 4 (2.7 mU/l); thyroid hormone supplementation was then started. Before the initiation of GH treatment, morning cortisol levels were normal (at 8 h, 0.22 mmol/l), but at the age of 11 years, the analysis was repeated and he had low cortisol levels: at 8 h, 0.04 mmol/l (reference 0.2-0.8 mmol/l) and 14 h, 0.06 mmol/l (reference 0.1-0.4 mmol/l), ACTH was also low (12 ng/l, reference 20-80 ng/l), and therefore hydrocortisone treatment was started. At the age of 13 years, he was still totally prepubertal (Tanner stage G1 P1) with low LH (1.0 U/l) and FSH (1.8 U/l) values; at the age of 13 years and 10 month, he was still prepubertal, with a low testosterone for his age (!0.1 nmol/l); induction of puberty was started. The patient has complete pituitary hormone deficiency and continued GH treatment after reaching adulthood. He has severe behavioral problems. The father's adult height SDS is K1.0 (174 cm), and the mother's adult height SDS 0.8 (174 cm).
Functional studies
We performed structural and functional studies to determine the mechanism by which the OTX2 Pro134Arg mutation affects target gene expression. EMSA showed that both mutant and WT proteins bind to the OTX2 consensus site ( Fig. 2A) ; the amount of protein synthesized was equivalent between WT and the mutant (data not shown).
The ability of WT and mutant Pro134Arg OTX2 protein to activate gene expression was measured using www.eje-online.org luciferase reporter gene assay systems. The construct containing the multiple bicoid binding site fused to a luciferase reporter gene was cotransfected with expression plasmids containing either WT or mutant OTX2 into a heterologous 293T human embryonal cell line ( Fig. 2B ) or GN cell line, a GNRH expressing neuronal cell line (Fig. 2C ). In 293T cells, WT OTX2 induced a 1.9G0.08-fold increase (48%) in luciferase activity relative to expression from pSG5EV. Transfection of equivalent amounts of WT and empty expression vector similarly demonstrated a 1.5-fold increase (34%) in transactivation. While maintaining a constant amount of WT Otx2, increasing amounts of mutant OTX2 plasmid (ratios of 1:2 and 1:1, WT:mutant DNA) were contransfected, resulting in significant, (40 and 53% respectively) inhibition of luciferase expression. Further inhibition (65%) was seen with transfection of the mutant OTX2 plasmid alone. Cotransfection of WT OTX2 and the multiple bicoid binding site reporter luciferase construct into GN cells induced a 2.25G0.17 increase (56%) in transactivation. Similar to the studies on 293T cells, transfecting a constant amount of WT OTX2 with increasing amounts of mutant OTX2 at ratios of 1:2 and 1:1 led to a decrease in luciferase expression (77.4 and 82.3% inhibition respectively). Cotransfection of equal amounts of WT and mutant OTX2 demonstrated an 83% decrease in expression.
Discussion
We performed OTX2 mutation screening by direct sequencing in 92 Dutch CPHD patients. We identified a novel missense mutation, p.Pro134Arg, in a patient with pituitary malformation, complete pituitary hormone deficiency, an underdeveloped left optic nerve, and severe behavioral problems. The patient's father is a carrier of the same mutation. He has a completely unremarkable phenotype and there are no other affected members in the family. The same amino acid was mutated in a patient published by Ragge et al. (8) , but in that patient, the change was to alanine. The fact that the unaffected mother of Ragge's patient had the same mutation and that Chatelain et al. (21) could not demonstrate the negative effect of the mutant in vitro suggests that the p.Pro134Ala sequence variant probably was not a major contributor to the phenotype. Importantly, alanine is a neutral, nonpolar, and hydrophobic amino acid whereas arginine is basic, positively charged, and hydrophilic. The difference in chemical characteristics between these amino acids suggests that the p.Pro134Arg mutation may have a different functional impact than p.Pro134Ala.
Furthermore, we identified a new silent mutation, c.768COT, not described till date in any control or patient population. None of the newly identified variants were present in the latest update (September 2011) of 1000 Genomes Project (http://browser. 1000genomes.org), where 1092 individuals were sequenced with low coverage and exome sequencing. Besides, several research groups previously sequenced OTX2 in large European control populations: 164 controls were sequenced by Ragge et al. (8) , 96 controls by Wyatt et al. (6) , and 181 controls were sequenced by Henderson et al. (15) . The two variants we describe in the present work were never reported in any of these studies.
Our CPHD cohort included three CPHD patients with eye malformations. Apart from the CPHD cohort, the HYPOPIT study includes an IGHD cohort of which two patients had eye malformations. We directly sequenced all 92 CPHD patients as well as the two IGHD patients with eye malformations and found that both were WT for OTX2. Table 1 shows the clinical characteristics of all five, CPHD and IGHD, patients. Only one patient from our study had an underdeveloped optic nerve; the other four patients had ocular malformation related to septo-optic dysplasia (SOD). It is remarkable that the OTX2 mutation happened to be present in the only patient with an underdeveloped optic nerve and not among the four patients with other SOD-related ocular malformation.
The Pro134Arg mutation is located outside the DNA binding domains of the OTX2 protein; therefore, as would be expected, no alterations in binding affinity would be predicted. Indeed, EMSA showed that binding to the consensus site by the mutant protein was similar to that of the WT protein ( Fig. 2A) . Functional expression studies demonstrate that the OTX2 Pro134Arg mutant protein inhibited target gene expression in a dominant negative fashion using a luciferase reporter fused with a multiple bicoid binding site and expressing increasing concentrations of mutant OTX2 protein ( Fig. 2B and C) . The multiple bicoid binding site is identical to the OTX2 core binding motif described in the Hesx1 promoter, a known target of OTX2 (12, 14) . As the mutation is present in the heterologous state, our studies were developed to determine whether dominant negative inhibition was the mechanism for target gene repression. Increased target expression was clearly shown in cells transfected with WT Otx2; however, despite keeping the amount of transfected WT Otx2 DNA constant, the cotransfection of mutant Otx2 leads to a significant decrease in reporter expression. In the 293T cells, inhibition became more significant with increasing amounts of mutant Otx2. Interestingly, the mutant OTX2 demonstrated an even more dramatic inhibition of reporter expression in the GNRH expressing cell line. We believe that this further highlights the importance of this mutation given that our group has recently demonstrated OTX2 mRNA expression in GN cells (data not shown). As others have shown that the GNRH promoter contains the OTX2 binding site and OTX2 is required for GNRH expression (22) , our functional studies further support the role for the mutant protein in the pathogenesis of the central hypogonadism in addition to the other pituitary deficiencies seen in our patient.
The complexity of the OTX2 genotype/phenotype relationship is enormous. Our patient's phenotype is severe and can be explained by the dominant negative mutation. However, the father, being a carrier of the same mutation, should have at least some phenotypic anomalies. Further in vivo modeling studies would be required to find the mechanism and other possible factors that could protect from the severe effect of dominant negative inhibition.
To date, 29 different OTX2 mutations have been reported in 32 unrelated patients, including the new missense mutation found in our study ( Table 2 , Figs 3 and 4). The first described genetic defects that affected the OTX2 gene were interstitial deletions at 14q22, in association with AO and pituitary abnormalities (4, 5) . Using the candidate gene approach, Table 2 OTX2 mutations reported till date. Description of mutations is based on the NM_172337.1 reference sequence, followed HGVS recommendations (www.hgvs.org/mutnomen).
Position C1 refers to the A position of the ATG initiation codon for that gene. Nomenclature may differ from the notation used in the original publication. The novel mutation is in bold type. (6, 9) . HESX1 is an important transcription factor involved in pituitary development. HESX1 has been shown to be a transcriptional target of OTX2 (11, 12); thus, our current screening of OTX2 was a logical step following our previous search for HESX1 mutations (19) .
The pathogenicity of the OTX2 mutations is not easy to interpret, although several studies performed a detailed analysis of the biological effects of these mutations (7, 13, 14, 21) . The inheritance pattern of the OTX2 mutations is usually described as autosomal recessive with variable phenotype. Incomplete penetrance has been described in many families (6, 7, 8, 17) . This would explain the existence of unaffected carriers, like the father of our patient.
A relatively large number of alterations were found to be de novo, especially in all cases with whole gene deletions and translocations (4, 5, 6, 7, 8, 13, 16, 23) . The remarkable exception to this is the duplication of 14q22.3 (24) that was inherited from the affected father and was present in several family members with less severe developmental delay. However, some cases add more complexity to this pattern, like two cases of gonosomatic mosaicism inheritance described by Ragge et al. (8) (Table 2 : mutations 1, 25a and b). Moreover, Wyatt et al. (6) describe a family where normal parents without mutations had two affected children with the same mutation but different phenotypes (Table 2: mutation 4); parental mosaicism was excluded in blood and buccal cells. In many cases, one or several relatives are carriers of the same mutation and have apparently normal or mild phenotype (Table 2: mutations 2, 5, 11, 12, 13, 15, 16, and 29). In this regard, it should be noted that all mutations and deletions found to date are strictly heterozygous, although several cases with additional mutations in other genes have been described (6, 25) (Table 2 : mutations 2 and 25c). The above-mentioned cases suggest the existence of other genetic or environmental factors that influence the phenotype of patients with OTX2 mutations. Similar phenomena are seen in mouse models; for example, the Otx2-null mice have a severe head phenotype, but heterozygous animals have a variable phenotype ranging from apparent normality to severe developmental eye and head abnormalities depending on genetic background (1, 2, 3) .
It is known that prenatal exposure to teratogens can cause eye malformation; therefore, environmental factors may also play a role in the phenotype and explain some of the differences between individuals with the same mutation. In at least two cases, the mothers of the patients reported exposure to probably damaging factors during pregnancy (8) ( Table 2 : mutations 1 and 13).
In order to draw global conclusions from the mutational analyses performed to date, we summarized the known 29 OTX2 mutations together with the reported phenotypic data in Table 2 and Figs 2 and 3. Mutations within OTX2 are found throughout the gene, affecting all three coding exons. However, the distribution seems to have several hotspots affecting functional domains like the homeobox, the nuclear retention signal, or the highly conserved SIWSPA peptide sequence ('SIWSPA conserved motif ', Fig. 4 ). There are several mutations affecting the same amino acid, in various unrelated patients with different phenotypes ( Table 2 : mutations 9 and 10; 17 and 18; 25, 27, 28). Most mutations are located in conserved residues (Fig. 4) , which suggest functional relevance. However, their importance is not always functionally proven.
There seems to be a clear relationship between the localization of the reported mutations and clinical phenotype. Mutations in the N-terminus show very severe eye malformations without pituitary phenotype, while mutations localized to the C-terminus are associated with pituitary malformation and CPHD. All patients reported to date with CPHD, IGHD, or short stature have their mutations in exon 5, except for p.Lys74SerfsX30 (K74fs in Fig. 3 ). Although many patients have growth retardation or developmental problems during childhood, most of them are born with weights and lengths within the normal range. Patients with CPHD, IGHD, or short stature are overrepresented in the nuclear retention signal and OTX family domain (Fig. 3) . Additional research is needed to provide better understanding of the different functional regions of OTX2.
Another conclusion that can be drawn when reviewing the literature is that alterations in the OTX2 affect both genders equally; furthermore, there does not seem to be any relationship between the localization of the mutations and their inheritance (paternal, maternal inheritance, or de novo).
Although several investigators have already implicated mechanisms and potential additional factors by which OTX2 mutations can cause the associated phenotype, further research is needed to more clearly define the role of OTX2 in pituitary pathology. Our current studies provide further support for the important role of OTX2 as a candidate gene in genetic screening in patients with CPHD. In addition, we provide further evidence regarding the association between mutations in the C-terminus of the OTX2 gene and clinical presentation of pituitary abnormalities, therefore emphasizing the need for a careful evaluation of the genetic sequence in this area of the OTX2 gene.
